Axogen, Inc. — Director's Dealing 2021

Jun 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Axogen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2021-06-17

Reporting Person: Freitag Gregory Gene (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-17	Common Stock	M	9250	$19.17	Acquired	364556	Direct
2021-06-17	Common Stock	F	8781	$20.92	Disposed	355775	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-17	Employee Stock Option (right to purchase)	$19.17	M	9250	Disposed	2028-12-27	Common Stock (9250.0)	Direct

Footnotes

F1: Of the 8,781 reported shares, 8,477 shares were swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule 16b-3. Additionally, 304 shares of common stock were surrendered to satisfy the reporting person's tax withholding liability. In total, the reporting person received 469 additional shares of common stock.

F2: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.